Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2004 | Original Article

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma

Authors: Tatsuo Torizuka, Fumitoshi Nakamura, Toshihiko Kanno, Masami Futatsubashi, Etsuji Yoshikawa, Hiroyuki Okada, Masahide Kobayashi, Yasuomi Ouchi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2004

Abstract

This study was designed to determine the value of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in the early assessment of therapy response in lymphoma patients. We studied 20 patients with pathologically proven lymphoma, including 17 patients with aggressive non-Hodgkin’s lymphoma and three patients with Hodgkin’s lymphoma. All patients underwent whole-body FDG-PET imaging at baseline and after 1–2 cycles of chemotherapy. PET images were analysed visually and quantitatively by calculating the standardised uptake value (SUV). In each patient, we measured the SUV of the tumour demonstrating the highest FDG uptake at baseline study and the SUV of the same tumour after 1–2 cycles of therapy. The achievement of complete response was assessed on the basis of a combination of clinical findings and the results of conventional imaging modalities. Follow-up of progression-free survival (PFS) was obtained for the validation of PET data. Of the 20 patients, ten achieved complete remission at the completion of chemotherapy and the other ten did not respond to chemotherapy. Of the ten responders, four are still in remission (PFS 24–34 months) while the other six have relapsed (PFS 8–16 months). For the prediction of 24-month clinical outcome, visual analysis of PET after 1–2 cycles showed high sensitivity (87.5%) and accuracy (80%) but low specificity (50%). Comparison with the baseline SUVs revealed that the responders showed a significantly greater percent reduction in SUV after 1–2 cycles of therapy as compared with the non-responders (81.2%±9.5% vs 35.0%±20.2%, P<0.001). In addition, using 60% reduction as a cut-off value, the responders were clearly separated from the non-responders, with the exception of one non-responder. In conclusion, when performed early during chemotherapy, FDG-PET may be predictive of clinical outcome and allows differentiation of responders from non-responders in cases of aggressive lymphoma.

Canellos GP. CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol 1997; 15:1713–1716.PubMed

Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993; 328:1002–1006.PubMed

Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329:987–994.PubMed

Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931–933.PubMed

Delcambre C, Reman O, Henry-Amar M, et al. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27:176–184.PubMed

Front D, Ben-Haim S, Israel O, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182:359–363.PubMed

Israel O, Mor M, Epelbaum R, et al. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002; 94:873–878.CrossRefPubMed

Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with⁶⁷Ga scintigraphy. Radiology 2000; 214:253–257.PubMed

Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36:1811–1817.PubMed

10.

Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin’s lymphoma to¹³¹I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 2000; 41:999–1005.PubMed

11.

Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using¹⁸F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930–2934.PubMed

12.

Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, Bihl H. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91:302–310.CrossRefPubMed

13.

Schoder H, Meta J, Yap C, et al. Effect of whole-body¹⁸F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42:1139–1143.PubMed

14.

Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging 2002; 29:797–803.CrossRefPubMed

15.

Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using¹⁸F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429–433.PubMed

16.

Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([¹⁸F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [¹⁸F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414–419.PubMed

17.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018–1027.PubMed

18.

Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-d-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207:431–437.PubMed

19.

Yutani K, Tatsumi M, Shiba E, Kusuoka H, Nishimura T. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis. J Nucl Med 1999; 40:1003–1008.PubMed

20.

Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[¹⁸F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMed

21.

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333:1540–1545.PubMed

22.

Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4:160–164.PubMed

23.

Engelhard M, Meusers P, Brittinger G, et al. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 1991; 2:177–180.PubMed

24.

Thomas F, Cosset JM, Cherel P, Renaudy N, Carde P, Piekarski JD. Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin’s disease. Radiother Oncol 1988; 11:119–122.PubMed

25.

Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464–4471.PubMed

26.

Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13:588–595.PubMed

27.

Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leuk Lymphoma 2000; 39:543–553.PubMed

Title: Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma
Authors: Tatsuo Torizuka
Fumitoshi Nakamura
Toshihiko Kanno
Masami Futatsubashi
Etsuji Yoshikawa
Hiroyuki Okada
Masahide Kobayashi
Yasuomi Ouchi
Publication date: 01-01-2004
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-003-1333-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2004

Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner

European Board of Nuclear Medicine Multiple Choice Questions - 2003

The EJNM, an integrative vehicle for information transfer in nuclear medicine and molecular imaging

Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study

Positron flight in human tissues and its influence on PET image spatial resolution

Evidence that 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines